Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.14
ESRX's Cash to Debt is ranked lower than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.07 vs. ESRX: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
ESRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.25 Max: No Debt
Current: 0.14
Equity to Asset 0.31
ESRX's Equity to Asset is ranked lower than
52% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.32 vs. ESRX: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
ESRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.32 Max: 0.55
Current: 0.31
0.11
0.55
Interest Coverage 7.18
ESRX's Interest Coverage is ranked lower than
63% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.49 vs. ESRX: 7.18 )
Ranked among companies with meaningful Interest Coverage only.
ESRX' s Interest Coverage Range Over the Past 10 Years
Min: 4.51  Med: 8.18 Max: 16.5
Current: 7.18
4.51
16.5
F-Score: 8
Z-Score: 3.23
M-Score: -2.82
WACC vs ROIC
7.58%
10.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 4.75
ESRX's Operating margin (%) is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.16 vs. ESRX: 4.75 )
Ranked among companies with meaningful Operating margin (%) only.
ESRX' s Operating margin (%) Range Over the Past 10 Years
Min: 2.98  Med: 4.65 Max: 6.06
Current: 4.75
2.98
6.06
Net-margin (%) 2.70
ESRX's Net-margin (%) is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.45 vs. ESRX: 2.70 )
Ranked among companies with meaningful Net-margin (%) only.
ESRX' s Net-margin (%) Range Over the Past 10 Years
Min: 1.4  Med: 2.67 Max: 3.53
Current: 2.7
1.4
3.53
ROE (%) 17.20
ESRX's ROE (%) is ranked higher than
75% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.51 vs. ESRX: 17.20 )
Ranked among companies with meaningful ROE (%) only.
ESRX' s ROE (%) Range Over the Past 10 Years
Min: 8.16  Med: 34.38 Max: 87.47
Current: 17.2
8.16
87.47
ROA (%) 5.31
ESRX's ROA (%) is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.81 vs. ESRX: 5.31 )
Ranked among companies with meaningful ROA (%) only.
ESRX' s ROA (%) Range Over the Past 10 Years
Min: 3.3  Med: 9.22 Max: 14.42
Current: 5.31
3.3
14.42
ROC (Joel Greenblatt) (%) 379.76
ESRX's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 75.28 vs. ESRX: 379.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 220.38  Med: 464.57 Max: 589.99
Current: 379.76
220.38
589.99
Revenue Growth (3Y)(%) 5.30
ESRX's Revenue Growth (3Y)(%) is ranked lower than
68% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.70 vs. ESRX: 5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 22 Max: 69.7
Current: 5.3
5.3
69.7
EBITDA Growth (3Y)(%) 15.50
ESRX's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.50 vs. ESRX: 15.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.2  Med: 22.8 Max: 91
Current: 15.5
3.2
91
EPS Growth (3Y)(%) 25.50
ESRX's EPS Growth (3Y)(%) is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.10 vs. ESRX: 25.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 25.5 Max: 74.6
Current: 25.5
1.4
74.6
GuruFocus has detected 2 Warning Signs with Express Scripts Holding Co $ESRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ESRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ESRX Guru Trades in Q1 2016

David Dreman 15,504 sh (New)
George Soros 3,000 sh (New)
Leucadia National 3,800 sh (New)
Barrow, Hanley, Mewhinney & Strauss 9,772,328 sh (New)
Jim Simons 628,139 sh (New)
Paul Tudor Jones 57,136 sh (+396.66%)
Ray Dalio 394,218 sh (+323.15%)
Joel Greenblatt 1,158,428 sh (+224.25%)
Robert Olstein 131,100 sh (+167.55%)
Manning & Napier Advisors, Inc 3,655,550 sh (+6.33%)
Charles Brandes 2,168,388 sh (+6.20%)
Jeff Auxier 74,035 sh (+0.05%)
First Eagle Investment 1,168 sh (unchged)
Samuel Isaly 378,000 sh (unchged)
Steve Mandel Sold Out
Ruane Cunniff Sold Out
Scott Black Sold Out
First Pacific Advisors Sold Out
Wallace Weitz 1,057,939 sh (-0.05%)
HOTCHKIS & WILEY 1,554,950 sh (-2.22%)
Mario Gabelli 108,748 sh (-5.46%)
Chris Davis 5,142,979 sh (-7.03%)
Dodge & Cox 22,069,813 sh (-13.52%)
Ken Fisher 375,624 sh (-19.17%)
David Rolfe 3,987,074 sh (-22.13%)
Keeley Asset Management Corp 9,629 sh (-39.13%)
Jeremy Grantham 1,624,557 sh (-49.28%)
Diamond Hill Capital 3,394 sh (-99.77%)
Pioneer Investments 3,190 sh (-99.84%)
» More
Q2 2016

ESRX Guru Trades in Q2 2016

Larry Robbins 72,122 sh (New)
Arnold Van Den Berg 97,615 sh (New)
Paul Tudor Jones 526,800 sh (+822.01%)
David Dreman 27,122 sh (+74.94%)
Barrow, Hanley, Mewhinney & Strauss 14,646,371 sh (+49.88%)
Robert Olstein 131,100 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Jeff Auxier 74,035 sh (unchged)
Pioneer Investments Sold Out
Leucadia National Sold Out
George Soros Sold Out
Jim Simons Sold Out
Keeley Asset Management Corp Sold Out
Wallace Weitz 1,046,771 sh (-1.06%)
Dodge & Cox 21,691,413 sh (-1.71%)
Charles Brandes 2,126,580 sh (-1.93%)
Manning & Napier Advisors, Inc 3,569,730 sh (-2.35%)
Chris Davis 4,955,717 sh (-3.64%)
Ken Fisher 352,068 sh (-6.27%)
Mario Gabelli 97,743 sh (-10.12%)
Joel Greenblatt 962,979 sh (-16.87%)
Diamond Hill Capital 2,785 sh (-17.94%)
David Rolfe 3,251,358 sh (-18.45%)
Ray Dalio 311,618 sh (-20.95%)
Jeremy Grantham 1,127,881 sh (-30.57%)
HOTCHKIS & WILEY 775,261 sh (-50.14%)
Samuel Isaly 318,800 sh (-15.66%)
» More
Q3 2016

ESRX Guru Trades in Q3 2016

Richard Pzena 3,507 sh (New)
Larry Robbins 640,960 sh (+788.72%)
Ray Dalio 403,218 sh (+29.39%)
Barrow, Hanley, Mewhinney & Strauss 17,407,316 sh (+18.85%)
Robert Olstein 142,000 sh (+8.31%)
Charles Brandes 2,129,437 sh (+0.13%)
First Eagle Investment 1,168 sh (unchged)
Diamond Hill Capital Sold Out
Jeremy Grantham Sold Out
HOTCHKIS & WILEY Sold Out
Samuel Isaly Sold Out
Jeff Auxier 73,995 sh (-0.05%)
Dodge & Cox 21,410,369 sh (-1.30%)
Ken Fisher 347,357 sh (-1.34%)
Arnold Van Den Berg 96,155 sh (-1.50%)
Wallace Weitz 1,000,693 sh (-4.40%)
Manning & Napier Advisors, Inc 3,387,898 sh (-5.09%)
David Rolfe 3,066,390 sh (-5.69%)
Chris Davis 4,638,868 sh (-6.39%)
Joel Greenblatt 871,757 sh (-9.47%)
David Dreman 12,314 sh (-54.60%)
Mario Gabelli 4,880 sh (-95.01%)
Paul Tudor Jones 5,800 sh (-98.90%)
» More
Q4 2016

ESRX Guru Trades in Q4 2016

Ken Fisher 353,137 sh (+1.66%)
Arnold Van Den Berg Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 446110    SIC: 5912
Compare:NYSE:AET, NYSE:CI, NYSE:HUM, NYSE:ANTX, NYSE:CNC, NYSE:WCG, NYSE:MOH, NAS:MGLN, NYSE:CVS, NYSE:UAM, NAS:HIIQ, NAS:CNXR, OTCPK:WCUI, OTCPK:OPRX, NYSE:UNH » details
Traded in other countries:ESRX34.Brazil, 4XS.Germany, ESRX.Mexico, ESRX.Switzerland, 0R0W.UK,
Express Scripts Holding Co offers healthcare management & administration services such as managed care organizations, health insurers, workers' compensation plans & government health programs.

Express Scripts Holding Co was incorporated in the State of Delaware on July 15, 2011 as Aristotle Holding, Inc. It operates as a Pharmacy benefit management in North America. It includes HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans and government health programs. It helps health benefit providers address access and affordability concerns resulting from rising drug costs while helping to improve healthcare outcomes. It works with clients, manufacturers, pharmacists and physicians to increase efficiency in the drug distribution chain, to manage costs in the pharmacy benefit and to improve members' health outcomes and satisfaction. The Company supports healthier outcomes by applying science to health decisions. It offers solutions in four areas namely benefit choices, drug choices, pharmacy choices and health choices. Health Decision ScienceSM is the Company's approach to understand and improve the decisions that impact clinical and financial outcomes and applies principles and knowledge from three disciplines: behavioral sciences, clinical specialization and actionable data. These disciplines form a powerful combination that seeks to increase the likelihood of healthier decisions and healthier outcomes. Consumerology(r), or the application of the behavioral sciences to healthcare, optimizes decision mechanisms and helps make decisions easier. Therapeutic Resource CentersSM gives patients access to specialist pharmacists and nurses to close gaps in care. It has organized its operations into two business segments based on products and services offered PBM and Business Operations. The Company's PBM segment consists services such as the retail network pharmacy administration, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management, clinical solutions to improve health outcomes, such as adherence, case coordination and personalized medicine, flexible array of Medicare Part D, Medicaid and Health Insurance Marketplace offerings to support clients' benefits, specialty pharmacy, including the distribution of fertility pharmaceuticals requiring special handling or packaging, administration of a group purchasing organization and consumer health and drug information. The Business Operations segment consists of distribution of pharmaceuticals and medical supplies to providers and clinics and scientific evidence to guide the safe, effective and affordable use of medicines. The Company is subject to federal and state laws and regulations.

Guru Investment Theses on Express Scripts Holding Co

Weitz Funds Comments on Express Scripts - Nov 11, 2016

Express Scripts (NASDAQ:ESRX) is the largest independent pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. As the U.S. election enters its final stages, pharmaceutical manufacturers have shouldered a significant portion of the public’s frustration with the growing lack of affordability in healthcare. In recent weeks, several drug companies have attempted to shift the conversation by pointing fingers at PBMs and other “middlemen” as contributing to (as opposed to minimizing) rising prescription drug costs. Express Scripts and its peers provide a necessary and valuable service to plan sponsors, constructing custom plan designs that balance customer desires for access, cost and flexibility. Providing the absolute lowest cost for each drug utilized is not often the sponsor’s only (or even primary) goal. Additionally, competitive intensity across the industry is high, with no less than two (and in most cases three) potential PBM models to choose from for managing drug costs. We believe Express Scripts keeps a reasonable amount of the savings it generates for clients (we estimate between 10-15%) and that demand for its services will remain high as cost challenges persist. Express Scripts’ shares currently trade at a meaningful discount to our estimate of intrinsic value.



  • From Weitz Balanced Fund third quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Express Scripts - Nov 08, 2016

QVC Group (NASDAQ:QVCA) is owned by Liberty Interactive. QVC is an American television network and multinational corporation specializing in televised and online shopping experiences. Shares of QVC Group fell after management indicated that its U.S. business had experienced significant sales headwinds, which are likely to continue into the next quarter. QVC’s U.S. business, which has not seen a sales decline since the Great Recession, appears to be tracking down in the mid to high single- digits, as its fashion business has slowed and a large beauty vendor is dealing with customer complaints on its hair care products. Importantly, we don’t view these issues as a sign of the QVC model suddenly being broken. QVC’s customer retention and loyalty remain strong, as does viewership of their network. Additionally, the international businesses appear unaffected by the current U.S.-centric slowdown. Although the decline in QVC shares is disappointing, we believe management will take advantage, growing their per share business value by continuing to execute their share repurchase strategy.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

David Rolfe Comments on Express Scripts - Jul 13, 2016

Express Scripts (NASDAQ:ESRX) was a top contributor during the quarter. The stock recovered some of the poor performance from the first quarter after Anthem management noted that, despite filing a lawsuit over Express Scripts’s pricing, they believed any ruling on the lawsuit would take several years and were still open to negotiations. Express Scripts is the sole, independent pharmacy benefits manager (PBM), which we think is key for maintaining their alignment with customers. We continue to expect Express Scripts to drive mid-to-high single-digit EBITDA growth using its scale to negotiate better pricing with drug manufacturers and service providers, while increasing patient adherence. We think earnings per share can continue to grow at a double-digit rate as shares are repurchased at what, in our view, are attractive valuations. That said, as shares rallied from their previous lows, we reduced the stock's weighting to better reflect the risk/reward of Express Scripts’s growth and valuation.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

Brandes Investments Comments on Express Scripts - Jun 15, 2016

Express Scripts (NASDAQ:ESRX) declined 20% during the quarter due to a dispute with its largest client, health insurer Anthem (which accounts for 15%-20% of Express Scripts’ sales), as Anthem believes that Express Scripts needs to pass on larger drug cost savings to its customers. Under the existing contract, Anthem is entitled to a good-faith repricing of the contract terms, the deadline for which was December 15, 2015. As the deadline has passed and Express Scripts still has not provided Anthem with an offer that Anthem deems acceptable, Anthem has recently decided to take legal action against Express Scripts. Express Scripts’ CEO stated the company intends to resolve the dispute and keep Anthem as a customer.



We believe the market has over-reacted to the dispute as the current valuation prices in more than a complete loss of the Anthem contract. While there are multiple possibilities, we believe the most likely outcome is a renegotiation to extend the contract, likely at a lower margin but with increased volumes due to Anthem’s acquisition of Cigna. However there is a risk that Anthem switches to another vendor or brings the business in-house, although it lacks scale relative to peers. Given that the market seems to have priced in the worst-case outcome, we continue to believe that Express Scripts offers an attractive margin of safety.



From Brandes' Global Equity Fund first quarter 2016 commentary.



Check out Charles Brandes latest stock trades

Wallace Weitz Comments on Express Scripts - Apr 22, 2016

Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. Negotiations with Anthem, Express Scripts’ largest customer, hit an impasse early in the quarter. Anthem elected to bring the details of the disagreement public at a widely attended industry conference in January, providing the investment community a lens into how far the two companies were apart on the economics of their existing contract. Since then, Anthem has also filed a lawsuit against Express Scripts. While we hope a mutually agreeable solution will eventually be achieved, it remains possible (some believe likely) that Anthem will choose not to renew its contract with Express in 2019. We have run scenarios encompassing a range of different outcomes, and we believe Express Scripts’ shares are undervalued in all but the most dire. We continue to monitor contract-related developments and are otherwise heartened by improved execution across the other 84% of Express Scripts’ enterprise.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Dodge & Cox Comments on Express Scripts - Nov 19, 2015

Over the past decade, Express Scripts (NASDAQ:ESRX) has been a significant beneficiary of three industry trends: increased generic penetration, mail order pharmacy growth, and industry consolidation. The past round of mergers—CVS/Caremark, Express Scripts/Medco Health Solutions (Medco), and SXC Health Solutions/Catalyst Health—has created an oligopolistic market structure where the top three players now control over 65% of industry volumes.



Following its merger with Medco in 2012, Express Scripts became the largest PBM in the United States. The company now generates over $100 billion in annual revenue and manages 1.3 billion claims, or 30 percent of all U.S. prescription claims. Today, the company operates three vertically integrated businesses: a basic pharmacy benefit manager, a mail order pharmacy, and a specialty pharmacy. Express Scripts has achieved measurable growth by providing patients with generic drugs. With multiple equivalent treatments available, the company has used its buying power to save money for customers and generate profits; its mission is well aligned with customers looking to reduce health care and pharmacy cost trends. This strategy has boosted generic drug penetration to high levels.



The upcoming challenge for Express Scripts is in specialty drugs, which are used to treat chronic, complex diseases, including cancer, hepatitis, and multiple sclerosis. In the United States, this segment accounts for only 1% of volume, yet 25 to 30% of all drug spending. Biotech companies have maintained pricing power in this segment as disease complexity necessitates innovative and unique therapies. At over ten times the price of the average prescription, however, a need exists to manage the costs of these drugs, which we view as an attractive long-term growth opportunity. Express Scripts, with 30% market share in specialty drugs, is best positioned to help patients receive needed treatments cost effectively. Given the emergence of biosimilars and substitute treatments for older biotech drugs, Express Scripts’ strategy has the potential to influence prices in this segment.



During the second quarter, we increased the Fund’s position in Express Scripts after weighing the company’s fundamental outlook against its valuation. We believe Express Scripts’ strong business franchise, significant scale advantage, financial stability, growth opportunities, and reasonable valuation at 15.5 times forward earnings present an attractive investment opportunity. On June 30, Express Scripts was a 2.1% position in the Fund.





From Dodge & Cox Global Stock Fund second quarter 2015 commentary.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about Express Scripts Holding Co

Express Scripts to Include Harvoni in Hepatitis Cure Value Program The treatment cost will be reduced close to 50%
As announced by Express Scripts (NASDAQ:ESRX) through PR Newswire Dec. 12, the program that targets the treatment of patients affected with the hepatitis C virus, called “Hepatitis Cure Value Program,” will be upgraded with another product in January. Read more...
Weitz Funds Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) is the largest independent pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. As the U.S. election enters its final stages, pharmaceutical manufacturers have shouldered a significant portion of the public’s frustration with the growing lack of affordability in healthcare. In recent weeks, several drug companies have attempted to shift the conversation by pointing fingers at PBMs and other “middlemen” as contributing to (as opposed to minimizing) rising prescription drug costs. Express Scripts and its peers provide a necessary and valuable service to plan sponsors, constructing custom plan designs that balance customer desires for access, cost and flexibility. Providing the absolute lowest cost for each drug utilized is not often the sponsor’s only (or even primary) goal. Additionally, competitive intensity across the industry is high, with no less than two (and in most cases three) potential PBM models to choose from for managing drug costs. We believe Express Scripts keeps a reasonable amount Read more...
Wally Weitz Comments on Express Scripts Guru stock highlight
QVC Group (NASDAQ:QVCA) is owned by Liberty Interactive. QVC is an American television network and multinational corporation specializing in televised and online shopping experiences. Shares of QVC Group fell after management indicated that its U.S. business had experienced significant sales headwinds, which are likely to continue into the next quarter. QVC’s U.S. business, which has not seen a sales decline since the Great Recession, appears to be tracking down in the mid to high single- digits, as its fashion business has slowed and a large beauty vendor is dealing with customer complaints on its hair care products. Importantly, we don’t view these issues as a sign of the QVC model suddenly being broken. QVC’s customer retention and loyalty remain strong, as does viewership of their network. Additionally, the international businesses appear unaffected by the current U.S.-centric slowdown. Although the decline in QVC shares is disappointing, we believe management will take advantage, growing their per share business value by continuing to execute their share repurchase strategy. Read more...
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Determining when each ratio is more appropriate to use than the other
Introduction Read more...
Hell or High Water How a movie about robbing banks illuminates some of the fundamentals of value investing
You might not think a movie about robbing banks illuminates some of the fundamentals of value investing, but then again, you might not have seen "Hell or High Water." The movie tells the story of two brothers who traveled around rural Texas robbing small-town banks early in the morning to keep their family property out of foreclosure. It's not about the intricacies of their heist, it is the simplicity of the smaller banks they robbed. It is only when they got greedy, going after a bigger bank, that they got caught. Read more...
Arnold Van Den Berg Buys 6 New Stocks, Gets More Bullish on Oil Companies His firm expects $70 oil
During the second quarter, founder of Austin-based Century Management Arnold Van Den Berg (Trades, Portfolio) cut back on his sizable positioning in gold miners while increasing holdings in health care and oil. Read more...
Van Den Berg Made 6 New Buys in 2nd Quarter Most purchases were in health care, but largest was in mass media
Arnold Van Den Berg (Trades, Portfolio), who founded Century Management more than 40 years ago, invested in half a dozen new buys in the second quarter. Most of Van Den Berg’s new buys were in health care-related companies, but his largest was not. Read more...
David Rolfe Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) was a top contributor during the quarter. The stock recovered some of the poor performance from the first quarter after Anthem management noted that, despite filing a lawsuit over Express Scripts’s pricing, they believed any ruling on the lawsuit would take several years and were still open to negotiations. Express Scripts is the sole, independent pharmacy benefits manager (PBM), which we think is key for maintaining their alignment with customers. We continue to expect Express Scripts to drive mid-to-high single-digit EBITDA growth using its scale to negotiate better pricing with drug manufacturers and service providers, while increasing patient adherence. We think earnings per share can continue to grow at a double-digit rate as shares are repurchased at what, in our view, are attractive valuations. That said, as shares rallied from their previous lows, we reduced the stock's weighting to better reflect the risk/reward of Express Scripts’s growth and valuation. Read more...
Brandes Investments Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) declined 20% during the quarter due to a dispute with its largest client, health insurer Anthem (which accounts for 15%-20% of Express Scripts’ sales), as Anthem believes that Express Scripts needs to pass on larger drug cost savings to its customers. Under the existing contract, Anthem is entitled to a good-faith repricing of the contract terms, the deadline for which was December 15, 2015. As the deadline has passed and Express Scripts still has not provided Anthem with an offer that Anthem deems acceptable, Anthem has recently decided to take legal action against Express Scripts. Express Scripts’ CEO stated the company intends to resolve the dispute and keep Anthem as a customer. Read more...
Barrow Hanley Mewhinney & Strauss Invests in Express Scripts Guru adds to holdings in State Street and Marathon Petroleum
Barrow, Hanley, Mewhinney & Strauss became the second-largest shareholder among the gurus with its first-quarter purchase of a 9,772,328-share stake in Express Scripts Holding Co. (NASDAQ:ESRX), a St. Louis-based pharmacy benefit management services provider. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.20
ESRX's P/E(ttm) is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.85 vs. ESRX: 17.20 )
Ranked among companies with meaningful P/E(ttm) only.
ESRX' s P/E(ttm) Range Over the Past 10 Years
Min: 13.51  Med: 26.41 Max: 36.23
Current: 17.2
13.51
36.23
Forward P/E 10.66
ESRX's Forward P/E is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.97 vs. ESRX: 10.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.20
ESRX's PE(NRI) is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.85 vs. ESRX: 17.20 )
Ranked among companies with meaningful PE(NRI) only.
ESRX' s PE(NRI) Range Over the Past 10 Years
Min: 13.38  Med: 25.93 Max: 35.5
Current: 17.2
13.38
35.5
Price/Owner Earnings (ttm) 8.88
ESRX's Price/Owner Earnings (ttm) is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.05 vs. ESRX: 8.88 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ESRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.96  Med: 15.17 Max: 28.28
Current: 8.88
7.96
28.28
P/B 2.87
ESRX's P/B is ranked lower than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.43 vs. ESRX: 2.87 )
Ranked among companies with meaningful P/B only.
ESRX' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 6.93 Max: 31.78
Current: 2.87
1.85
31.78
P/S 0.46
ESRX's P/S is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.51 vs. ESRX: 0.46 )
Ranked among companies with meaningful P/S only.
ESRX' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 0.62 Max: 1.07
Current: 0.46
0.41
1.07
PFCF 9.32
ESRX's PFCF is ranked higher than
65% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.03 vs. ESRX: 9.32 )
Ranked among companies with meaningful PFCF only.
ESRX' s PFCF Range Over the Past 10 Years
Min: 8.32  Med: 14.52 Max: 25.83
Current: 9.32
8.32
25.83
POCF 8.71
ESRX's POCF is ranked higher than
53% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.61 vs. ESRX: 8.71 )
Ranked among companies with meaningful POCF only.
ESRX' s POCF Range Over the Past 10 Years
Min: 7.8  Med: 13.27 Max: 23.5
Current: 8.71
7.8
23.5
EV-to-EBIT 11.80
ESRX's EV-to-EBIT is ranked higher than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.99 vs. ESRX: 11.80 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.8  Med: 16.3 Max: 30.2
Current: 11.8
8.8
30.2
EV-to-EBITDA 8.08
ESRX's EV-to-EBITDA is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.13 vs. ESRX: 8.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.7  Med: 12.3 Max: 22.4
Current: 8.08
7.7
22.4
PEG 0.99
ESRX's PEG is ranked higher than
75% of the 12 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.36 vs. ESRX: 0.99 )
Ranked among companies with meaningful PEG only.
ESRX' s PEG Range Over the Past 10 Years
Min: 0.43  Med: 1.09 Max: 1.7
Current: 0.99
0.43
1.7
Shiller P/E 30.48
ESRX's Shiller P/E is ranked lower than
62% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 26.62 vs. ESRX: 30.48 )
Ranked among companies with meaningful Shiller P/E only.
ESRX' s Shiller P/E Range Over the Past 10 Years
Min: 27.23  Med: 46.11 Max: 79.91
Current: 30.48
27.23
79.91
Current Ratio 0.70
ESRX's Current Ratio is ranked lower than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.16 vs. ESRX: 0.70 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.84 Max: 2.21
Current: 0.7
0.55
2.21
Quick Ratio 0.59
ESRX's Quick Ratio is ranked lower than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.97 vs. ESRX: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.75 Max: 2.15
Current: 0.59
0.47
2.15
Days Inventory 6.97
ESRX's Days Inventory is ranked higher than
56% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.97 vs. ESRX: 6.97 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s Days Inventory Range Over the Past 10 Years
Min: 3.02  Med: 4.25 Max: 8.09
Current: 6.97
3.02
8.09
Days Sales Outstanding 25.03
ESRX's Days Sales Outstanding is ranked higher than
65% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 29.62 vs. ESRX: 25.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.97  Med: 21.38 Max: 37.15
Current: 25.03
13.97
37.15
Days Payable 14.87
ESRX's Days Payable is ranked lower than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 100.40 vs. ESRX: 14.87 )
Ranked among companies with meaningful Days Payable only.
ESRX' s Days Payable Range Over the Past 10 Years
Min: 5.7  Med: 11.5 Max: 14.87
Current: 14.87
5.7
14.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.10
ESRX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.20 vs. ESRX: 6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.4  Med: 0 Max: 6.1
Current: 6.1
-14.4
6.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.67
ESRX's Price/Projected FCF is ranked higher than
86% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.00 vs. ESRX: 0.67 )
Ranked among companies with meaningful Price/Projected FCF only.
ESRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.39 Max: 62.6
Current: 0.67
0.65
62.6
Price/DCF (Earnings Based) 0.81
ESRX's Price/DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.22 vs. ESRX: 0.81 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.76
ESRX's Price/Median PS Value is ranked higher than
88% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. ESRX: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
ESRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.94 Max: 1.72
Current: 0.76
0.5
1.72
Price/Peter Lynch Fair Value 1.07
ESRX's Price/Peter Lynch Fair Value is ranked higher than
64% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.26 vs. ESRX: 1.07 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ESRX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.42  Med: 1.09 Max: 2.44
Current: 1.07
0.42
2.44
Earnings Yield (Greenblatt) (%) 8.42
ESRX's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.10 vs. ESRX: 8.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.3  Med: 6.1 Max: 11.3
Current: 8.42
3.3
11.3
Forward Rate of Return (Yacktman) (%) 24.13
ESRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.15 vs. ESRX: 24.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 22.2  Med: 29.5 Max: 37.4
Current: 24.13
22.2
37.4

More Statistics

Revenue (TTM) (Mil) $101,600
EPS (TTM) $ 4.22
Beta0.93
Short Percentage of Float2.68%
52-Week Range $64.46 - 80.02
Shares Outstanding (Mil)616.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 101,957 104,778 108,076
EPS ($) 6.40 6.87 7.71
EPS w/o NRI ($) 6.40 6.87 7.71
EPS Growth Rate
(3Y to 5Y Estimate)
24.86%
Dividends Per Share ($)
» More Articles for ESRX

Headlines

Articles On GuruFocus.com
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
Mean Reversion and the Bell Curve Jan 03 2017 
Express Scripts to Include Harvoni in Hepatitis Cure Value Program Dec 13 2016 
Analysis of AmerisourceBergen's Dividend Increase Nov 17 2016 
Weitz Funds Comments on Express Scripts Nov 11 2016 
Weitz Balanced Fund 3rd Quarter Commentary Nov 11 2016 
Wally Weitz Comments on Express Scripts Nov 08 2016 
Wally Weitz's Partners Value Fund 3rd Quarter Commentary Nov 08 2016 

More From Other Websites
Express Scripts Holding Company Announces Fourth Quarter and Full Year 2016 Earnings Conference Call Jan 18 2017
Express Scripts Holding Co. breached its 50 day moving average in a Bullish Manner : ESRX-US :... Jan 11 2017
Mylan CEO: Trump a very business-minded, solution-oriente... Jan 10 2017
Mylan CEO: EpiPen started a much-needed conversation in h... Jan 10 2017
Express Scripts CEO: Many drug list prices are still too ... Jan 10 2017
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales Jan 06 2017
Cheating Death Can Cost $200,000 as Cancer Leads Sales Jan 06 2017
Express Scripts Holding Company to Present at the J.P. Morgan Healthcare Conference Jan 04 2017
Express Scripts Holding Company to Present at the J.P. Morgan Healthcare Conference Jan 04 2017
Bob Doll's top 5 stocks for 2017 Dec 21 2016
Why Healthcare and Trade Stocks Tempered Moat Index Upside Dec 20 2016
Year In Review 2016: Leadership changes at Express Scripts, Centene expansion headline health care Dec 19 2016
Factors behind Horizon Pharma’s Volatility in December Dec 19 2016
Mylan launching generic EpiPen Dec 16 2016
Express Scripts board adds 65 million shares to buyback program Dec 16 2016
EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Other Events Dec 16 2016
Express Scripts Not Worried About A Trump Presidency Dec 16 2016
The Zacks Analyst Blog Highlights: FedEx, Express Scripts, Mondelez, Lockheed Martin and Medtronic Dec 16 2016
Top Research Reports for FedEx, Mondolez & Express Scripts Dec 15 2016
Selloff In Express Scripts Surprising To Barclays Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)